A 6-month venographic follow-up in 164 patients with acute deep vein thrombosis

Thrombosis and Haemostasis

Volumn 78, Issue 2, 1997, Pages 803-807

  Holmström, Margareta ^a   Lindmarker, Per ^a   Granqvist, Staffan ^a   Johnsson, Hans ^a   Lockner, Dieter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; D DIMER; DALTEPARIN; HEPARIN; OROSOMUCOID;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; FEMALE; FOLLOW UP; GENDER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PHLEBOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBUS;

EID: 0030743003     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657632     Document Type: Article

References (21)

1. Leizorovicz A, Simonneau G, Decousus A, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994; 309: 299-304.
2. Lockner D. Low molecular weight heparin for treatment of established venous thromboembolism. In: Low molecular weight heparin in prophylaxis and therapy of thromboembolic disease. Bounameaux H, ed. Marcel Dekker Inc., Basel, 1995; 283-305.
3. ten Cate JW, Koopman M, Prins M, Büller HR. Treatment of venous thromboembolism. Thromb Haemost 1995; 75 (1): 197-203.
4. Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P, Hoeg V, Aandahl M, Haugen K, Laerum F, Scheel B, Sortland O, Vinje B. Subcutaneous heparin treatment of deep venous thrombosis with low molecular weight heparin. Haemostasis 1986; 16 (Suppl 2): 30-7.
5. Prandoni P, Lensing AWA, Büller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW. Comparison of subcutaneous low-molecular weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-5.
6. Lindmarker P, Holmström M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin® with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72: 186-90.
7. Duroux P, Beclere A. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis: A collaborative European multicentre study. Thromb Haemost 1991; 65: 251-6.
8. Bratt G, Törnebohm E, Granquist S, Åberg W, Lockner D. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the treatment of deep venous thrombosis. Thromb Haemost 1985; 54: 813-7.
9. Bratt G, Åberg W, Johansson M, Törnebohm E, Granquist S, Lockner D. Two daily subcutaneous injections of Fragmin® compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1990; 64: 506-10.
10. Common H, Seaman A, Rösch J, Porter J, Dotter C. Deep vein thrombosis treated with streptokinase or heparin. Angiology 1976; 27: 645-54.
11. Elliot M, Immelman P, Jeffery P, Benatar R, Funston M, Smith B, Shepstone J, Ferguson D, Jacobs P, Walker W, Louw J. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial. Br J Surg 1979; 66: 838-43.
12. Isacsson S, Nilsson IM. Defective fibrinolysis in blood and vein walls in recurrent idiopathic venous thrombosis. Acta Chir Scand 1972; 138: 313-9.
13. Conard J, Veuillet-Duval A, Horellou MH, Samama M. Etude de la coagulation et de la fibrinolyse dans 131 cas de thromboses vineuses récidivantes. Nouvelle Revue Francaise d'Hématologie 1982; 24: 205-9.
14. Schulman S, Wiman B and the DURAC Trial Study Group. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Thromb Haemost 1996; 75: 607-11.
15. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-44.
16. Marder VJ, Soulen RL, Atichartakarn V, Budzynski AZ, Parulekar S, Kim JR, Edward N, Zahavi J, Algazy KM. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89: 1118-29.
17. Marsh NA, Minter AJ, Chesterman CN. The effect of heparin and other glycosaminoglycans on levels of tissue plasminogen activator and plasminogen activator inhibitor in cultured human umbilical vein endothelial cells. Blood Coag and Fibrinolysis 1990; 1: 133-8.
18. Grulich-Henn J, Preissner KT, Müller-Berghaus G. Heparin stimulates fibrinolysis in mesothelial cells by selective induction of tissue-plasminogen activator but not plasminogen activator inhibitor-1 synthesis. Thromb Haemost 1990; 64: 420-5.
19. Chmielewska J, Wiman B. Determination of tissue plasminogen activator and its "fast" inhibitor in plasma. Clin Chem 1986; 32: 482-5.
20. Jansson J-H, Norberg B, Nilsson TK. Impact of acute phase on concentrations of tissue plasminogen activator and plasminogen activator inhibitor in plasma after deep-vein thrombosis or open-heart surgery. Clin Chem 1989; 35: 1544-5.
21. The DVTenox study group. Markers of the hemostatic system activation in acute deep venous thrombosis-evolution during the first days of heparin treatment. Thromb Haemost 1993; 70: 909-14.